Stock MCK MCKESSON CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials McKesson Corporation

Equities

MCK

US58155Q1031

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
543.3 USD +0.62% Intraday chart for McKesson Corporation +3.52% +17.35%
Apr. 24 McKesson Keeps Quarterly Dividend at $0.62 Per Share; Payable July 1 to Shareholders of Record on June 3 MT
Apr. 24 McKesson Corporation Declares Quarterly Dividend, Payable on June 3, 2024 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 22,455 23,952 31,044 45,858 48,757 71,394 - -
Enterprise Value (EV) 1 27,069 27,324 31,914 48,205 49,673 73,177 71,872 70,137
P/E ratio 689 x 27.3 x -6.9 x 42.3 x 14.2 x 24.7 x 19.6 x 18 x
Yield 1.29% 1.2% 0.86% 0.6% 0.59% 0.44% 0.51% 0.54%
Capitalization / Revenue 0.1 x 0.1 x 0.13 x 0.17 x 0.18 x 0.23 x 0.21 x 0.2 x
EV / Revenue 0.13 x 0.12 x 0.13 x 0.18 x 0.18 x 0.23 x 0.21 x 0.19 x
EV / EBITDA 6.37 x 6.34 x 7.33 x 9.14 x 9.27 x 13.6 x 12.4 x 11.3 x
EV / FCF 7.78 x 7.06 x 8.18 x 12.4 x 10.8 x 21.1 x 15.3 x 14.4 x
FCF Yield 12.9% 14.2% 12.2% 8.09% 9.26% 4.74% 6.54% 6.93%
Price to Book 2.75 x 4.3 x 179 x -19.5 x -27.3 x -27.5 x -27.3 x -45.2 x
Nbr of stocks (in thousands) 191,825 177,081 159,167 149,798 136,939 131,408 - -
Reference price 2 117.1 135.3 195.0 306.1 356.0 543.3 543.3 543.3
Announcement Date 5/8/19 5/20/20 5/6/21 5/5/22 5/8/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 214,319 231,051 238,228 263,966 276,711 311,917 337,668 362,950
EBITDA 1 4,248 4,309 4,354 5,276 5,357 5,369 5,785 6,211
EBIT 1 3,784 3,849 3,890 4,849 4,985 4,868 5,254 5,657
Operating Margin 1.77% 1.67% 1.63% 1.84% 1.8% 1.56% 1.56% 1.56%
Earnings before Tax (EBT) 1 610 1,144 -5,034 1,928 4,630 3,518 4,430 4,574
Net income 1 34 900 -4,539 1,114 3,560 3,034 3,525 3,704
Net margin 0.02% 0.39% -1.91% 0.42% 1.29% 0.97% 1.04% 1.02%
EPS 2 0.1700 4.950 -28.26 7.230 25.03 22.02 27.67 30.17
Free Cash Flow 1 3,479 3,868 3,901 3,899 4,601 3,469 4,703 4,859
FCF margin 1.62% 1.67% 1.64% 1.48% 1.66% 1.11% 1.39% 1.34%
FCF Conversion (EBITDA) 81.9% 89.77% 89.6% 73.9% 85.89% 64.61% 81.3% 78.22%
FCF Conversion (Net income) 10,232.35% 429.78% - 350% 129.24% 114.35% 133.42% 131.18%
Dividend per Share 2 1.510 1.620 1.670 1.830 2.090 2.401 2.746 2.940
Announcement Date 5/8/19 5/20/20 5/6/21 5/5/22 5/8/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 66,576 68,614 66,102 67,154 70,157 70,490 68,910 74,483 77,215 80,898 79,077 80,844 84,737 88,828 86,892
EBITDA 1 1,389 1,377 1,296 1,229 1,291 1,484 1,353 1,267 1,303 1,358 1,426 1,375 1,429 1,498 1,543
EBIT 1 1,278 1,273 1,204 1,137 1,197 1,393 1,258 1,170 1,208 1,261 1,285 1,268 1,304 1,358 1,417
Operating Margin 1.92% 1.86% 1.82% 1.69% 1.71% 1.98% 1.83% 1.57% 1.56% 1.56% 1.63% 1.57% 1.54% 1.53% 1.63%
Earnings before Tax (EBT) 1 442 - - - - 1,448 932 1,091 916 612 899 - - - -
Net income 1 267 -7 368 768 926 1,079 787 958 664 589 735.4 853.5 886 947 993
Net margin 0.4% -0.01% 0.56% 1.14% 1.32% 1.53% 1.14% 1.29% 0.86% 0.73% 0.93% 1.06% 1.05% 1.07% 1.14%
EPS 2 1.710 -0.0400 2.470 5.260 6.420 7.660 5.710 7.020 4.920 4.420 5.792 6.623 6.947 7.573 8.030
Dividend per Share 2 0.4700 0.4700 0.4700 0.4700 0.5400 0.5400 0.5400 0.5400 0.6200 0.6200 0.5912 0.6329 0.6931 0.7005 0.7119
Announcement Date 11/1/21 2/2/22 5/5/22 8/3/22 11/1/22 2/1/23 5/8/23 8/2/23 11/1/23 2/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 4,614 3,372 870 2,347 916 1,783 478 -
Net Cash position 1 - - - - - - - 1,257
Leverage (Debt/EBITDA) 1.086 x 0.7825 x 0.1998 x 0.4448 x 0.171 x 0.3321 x 0.0827 x -
Free Cash Flow 1 3,479 3,868 3,901 3,899 4,601 3,469 4,703 4,859
ROE (net income / shareholders' equity) 29.9% 41.2% 105% - - - 480% 138%
ROA (Net income/ Total Assets) 4.45% 4.49% 4.42% 5.69% 5.87% 5.77% 5.8% 5.88%
Assets 1 763.2 20,036 -102,780 19,570 60,612 52,565 60,753 62,952
Book Value Per Share 2 42.60 31.40 1.090 -15.70 -13.10 -19.70 -19.90 -12.00
Cash Flow per Share 2 20.50 24.00 28.30 28.80 36.30 31.00 39.30 43.60
Capex 1 557 506 641 535 558 571 605 627
Capex / Sales 0.26% 0.22% 0.27% 0.2% 0.2% 0.18% 0.18% 0.17%
Announcement Date 5/8/19 5/20/20 5/6/21 5/5/22 5/8/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for McKesson Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
543.3 USD
Average target price
559.5 USD
Spread / Average Target
+2.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.49% 4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
GALENICA AG Stock Galenica AG
-2.61% 3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.08% 3.64B
MEDIPAL HOLDINGS CORPORATION Stock MediPal Holdings Corporation
+7.96% 3.29B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. MCK Stock
  4. Financials McKesson Corporation